Neridronate therapy in the management of fracture risk

Neridronate is a nitrogen-containing bisphosphonate and in Italy it is licensed for the treatment of Osteogenesis Imperfecta (OI). Paget's disease of bone and type I Complex Regional Pain Syndrome. Differently from other bisphosphonates, neridronate can be administered both intravenously and intramuscularly. The latter regimen is noteworthy, especially because it does not require hospitalization and it is therefore suitable for homecare. Furthermore. both the intravenous and intramuscular regimens can prevent the possible side effects associated with the oral route. In this review we will discuss the data on the efficacy of neridronate for different conditions, from OI to post-menopausal osteoporosis, both in terms of bone mineral density changes and of anti-fracture benefit.